newsfilter
← Latest News
GlobeNewswire·

Agios Reports First Quarter 2025 Financial Results and Recent Business Highlights

– U.S. Regulatory Filing Under Active Review for Approval of PYRUKYND® (mitapivat) in Thalassemia, with PDUFA Goal Date of September 7, 2025 – – Phase 3 RISE UP Study of Mitapivat in Sickle Cell Disease On Track,